Table 2 Comparison between low and high LEF-1 expression groups regarding clinical data, laboratory data, and cytogenetic classification
Parameters | LEF1 | Test of significance | ||||||
|---|---|---|---|---|---|---|---|---|
Low expression < 4.82 log10N = 15 | High expression > 4.82 log10N = 15 | |||||||
Mean/N | SD/% | Mean/N | SD/% | Test | p value | Sig. | ||
Age | 61.0 | ± 10.2 | 37.7 | ± 8.4 | t = 6.82 | < 0.001 | HS | |
Sex | Male | 9 | 60.0% | 8 | 53.3% | F | 0.713 | NS |
Female | 6 | 40.0% | 7 | 46.7% | ||||
Hepatomegaly | No | 5 | 33.3% | 13 | 86.7% | X2 = 8.8 | 0.003 | HS |
Yes | 10 | 66.7% | 2 | 13.3% | ||||
Splenomegaly | No | 7 | 46.7% | 12 | 80.0% | X2 = 3.5 | 0.058 | NS |
Yes | 8 | 53.3% | 3 | 20.0% | ||||
Lymph-adenopathy | No | 10 | 66.7% | 12 | 80.0% | F | 0.682 | NS |
Yes | 5 | 33.3% | 3 | 20.0% | ||||
Hb (g/dL) | 6.9 | ± 2.2 | 9.4 | ± 1.4 | t = − 3.7 | 0.001 | HS | |
TLC (× 109/L) | 71.0 | ± 53.1 | 9.5 | ± 5.5 | t = 4.46 | 0.001 | HS | |
PLT (× 109/L) | 32.8 | ± 14.2 | 82.0 | ± 35.2 | t = − 5.0 | < 0.001 | HS | |
PB blast (%) | 52.1 | ± 28.3 | 19.5 | ± 10.6 | t = 4.19 | 0.001 | HS | |
BM blast (%) | 70.9 | ± 21.2 | 74.9 | ± 20.5 | t = − 0.5 | 0.603 | NS | |
Cytogenetics classification | Poor | 4 | 26.7% | 0 | 0.0% | F | 0.015 | S |
Intermediate | 9 | 60.0% | 7 | 46.7% | ||||
Good | 2 | 13.3% | 8 | 53.3% | ||||
Response to therapy at day 28 | Hematological Remission | 0 | 0.0% | 9 | 60.0% | F | < 0.001 | HS |
Incomplete Remission | 7 | 46.7% | 6 | 40.0% | ||||
Died | 8 | 53.3% | 0 | 0.0% | ||||
Overall survival (months) | 2.75 | ± 2.00 | 6.40 | ± 2.59 | t = 4.52 | < 0.001 | HS | |
Disease free survival (months) | - | - | 5.9 | ± 2.5 |  |  |  | |